Ongoing Insulin Pump Litigation Sees Court Hand Injunction to EOFlow

A district court has handed a preliminary injunction to EOFlow, blocking it from selling products developed using proprietary information derived from insulin pump maker Insulet — the decision arriving as Medtronic is slated to pay $738 million to acquire EOFlow.

EOFlow is also “restrained from disclosing” any Insulet trade secrets to “any third party, except as may be reasonably necessary for purposes of conducting this litigation, and in accordance with any applicable protective order,” read Friday’s order from the U.S. District Court for the District of Massachusetts.

The order specifically applies to multiple items pertaining to EOFlow’s EOPatch version 2 “to the extent that” Insulet trade secrets were used in their “design, development or creation,” said the injunction.

Read the district court injunction here.

To read the whole story, click here to subscribe.

Related Topics